ECSP12012156A - Hidrato del hidrobromuro de agomelatina y - Google Patents
Hidrato del hidrobromuro de agomelatina yInfo
- Publication number
- ECSP12012156A ECSP12012156A ECSP12012156A ECSP12012156A EC SP12012156 A ECSP12012156 A EC SP12012156A EC SP12012156 A ECSP12012156 A EC SP12012156A EC SP12012156 A ECSP12012156 A EC SP12012156A
- Authority
- EC
- Ecuador
- Prior art keywords
- hydrobromide
- present method
- agomelatine
- hydrate
- formula
- Prior art date
Links
- CKOVQQULGNBJAP-UHFFFAOYSA-N bromane Chemical compound Br.Br.Br CKOVQQULGNBJAP-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 abstract 2
- 229960002629 agomelatine Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporciona un hidrato del hidrobromuro de agomelatina de fórmula (I), en la que X es Br, preparación, uso y composición farmacéutica del mismo. Dicho hidrato obtenido mediante el presente método tiene una solubilidad significativamente aumentada que la agomelatina, y por ello es más adecuada para fabricar formulaciones farmacéuticas. Usando el presente método, se puede obtener una pureza elevada mediante de un proceso simple, sin ninguna etapa complicada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101262639A CN102190595A (zh) | 2010-03-17 | 2010-03-17 | 阿戈美拉汀溴化氢水合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12012156A true ECSP12012156A (es) | 2012-12-28 |
Family
ID=44599557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12012156 ECSP12012156A (es) | 2010-03-17 | 2012-09-14 | Hidrato del hidrobromuro de agomelatina y |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US8729132B2 (es) |
| EP (1) | EP2547650B1 (es) |
| JP (1) | JP5634533B2 (es) |
| KR (1) | KR101406736B1 (es) |
| CN (2) | CN102190595A (es) |
| AP (1) | AP3199A (es) |
| AU (1) | AU2011229619B2 (es) |
| BR (1) | BR112012023173B1 (es) |
| CA (1) | CA2792430C (es) |
| CL (1) | CL2012002541A1 (es) |
| CR (1) | CR20120461A (es) |
| CU (1) | CU20120136A7 (es) |
| CY (1) | CY1117134T1 (es) |
| DK (1) | DK2547650T3 (es) |
| EA (1) | EA022066B1 (es) |
| EC (1) | ECSP12012156A (es) |
| ES (1) | ES2572427T3 (es) |
| GE (1) | GEP20156232B (es) |
| GT (1) | GT201200260A (es) |
| HN (1) | HN2012001923A (es) |
| HR (1) | HRP20151343T1 (es) |
| HU (1) | HUE026673T2 (es) |
| IL (1) | IL221783A (es) |
| MA (1) | MA34054B1 (es) |
| ME (1) | ME02309B (es) |
| MX (1) | MX2012010594A (es) |
| MY (1) | MY160337A (es) |
| NI (1) | NI201200141A (es) |
| NZ (1) | NZ602451A (es) |
| PE (1) | PE20130014A1 (es) |
| PH (1) | PH12012501756A1 (es) |
| PL (1) | PL2547650T3 (es) |
| PT (1) | PT2547650E (es) |
| RS (1) | RS54449B1 (es) |
| SG (1) | SG183869A1 (es) |
| SI (1) | SI2547650T1 (es) |
| TN (1) | TN2012000436A1 (es) |
| UA (1) | UA105424C2 (es) |
| WO (1) | WO2011113363A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07115739B2 (ja) | 1986-03-19 | 1995-12-13 | 株式会社石田衡器製作所 | 多方向仕分け装置 |
| JPH07115742B2 (ja) | 1986-03-19 | 1995-12-13 | 株式会社石田衡器製作所 | 多方向仕分け装置 |
| JPH07115741B2 (ja) | 1986-03-19 | 1995-12-13 | 株式会社石田衡器製作所 | 多方向仕分け装置 |
| JPH07115740B2 (ja) | 1986-03-19 | 1995-12-13 | 株式会社石田衡器製作所 | 多方向仕分け装置 |
| FR2978916B1 (fr) | 2011-08-10 | 2013-07-26 | Servier Lab | Composition pharmaceutique solide pour administration buccale d'agomelatine |
| CN102718675B (zh) * | 2012-06-07 | 2015-03-25 | 上海右手医药科技开发有限公司 | 阿戈美拉汀甲磺酸复合物及其制备方法 |
| EP2851363B1 (en) * | 2012-05-14 | 2018-01-03 | Shanghai Righthand Pharmtech. Co., Ltd. | Agomelatine acid radical composite, and preparation method and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ES2204358T1 (es) * | 2000-10-30 | 2004-05-01 | Teva Pharmaceutical Industries Ltd. | Nuevas formas de cristal y de disolvente de hidrocloruro de ondasetron y procedimientos para su preparacion. |
| FR2890562B1 (fr) * | 2005-09-09 | 2012-10-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime |
| FR2899472B1 (fr) * | 2006-04-07 | 2008-09-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee |
| CN101481321B (zh) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | 阿戈美拉汀卤化氢复合物及其制备方法 |
| CN101585779B (zh) * | 2009-03-10 | 2014-04-02 | 上海医药工业研究院 | 阿戈美拉汀的晶型vi及其制备方法和应用 |
-
2010
- 2010-03-17 CN CN2010101262639A patent/CN102190595A/zh active Pending
-
2011
- 2011-03-17 EP EP11755680.3A patent/EP2547650B1/en active Active
- 2011-03-17 MY MYPI2012700614A patent/MY160337A/en unknown
- 2011-03-17 ME MEP-2016-9A patent/ME02309B/me unknown
- 2011-03-17 DK DK11755680.3T patent/DK2547650T3/en active
- 2011-03-17 PL PL11755680T patent/PL2547650T3/pl unknown
- 2011-03-17 UA UAA201211719A patent/UA105424C2/uk unknown
- 2011-03-17 SI SI201130723T patent/SI2547650T1/sl unknown
- 2011-03-17 WO PCT/CN2011/071912 patent/WO2011113363A1/en not_active Ceased
- 2011-03-17 PH PH1/2012/501756A patent/PH12012501756A1/en unknown
- 2011-03-17 GE GEAP201112870A patent/GEP20156232B/en unknown
- 2011-03-17 HR HRP20151343TT patent/HRP20151343T1/hr unknown
- 2011-03-17 CN CN201180024413.8A patent/CN102892749B/zh not_active Expired - Fee Related
- 2011-03-17 CA CA2792430A patent/CA2792430C/en active Active
- 2011-03-17 HU HUE11755680A patent/HUE026673T2/en unknown
- 2011-03-17 ES ES11755680T patent/ES2572427T3/es active Active
- 2011-03-17 SG SG2012065017A patent/SG183869A1/en unknown
- 2011-03-17 US US13/635,087 patent/US8729132B2/en active Active
- 2011-03-17 MX MX2012010594A patent/MX2012010594A/es active IP Right Grant
- 2011-03-17 AU AU2011229619A patent/AU2011229619B2/en not_active Ceased
- 2011-03-17 MA MA35191A patent/MA34054B1/fr unknown
- 2011-03-17 JP JP2012557393A patent/JP5634533B2/ja not_active Expired - Fee Related
- 2011-03-17 KR KR1020127026897A patent/KR101406736B1/ko not_active Expired - Fee Related
- 2011-03-17 RS RS20150831A patent/RS54449B1/sr unknown
- 2011-03-17 PE PE2012001449A patent/PE20130014A1/es active IP Right Grant
- 2011-03-17 PT PT117556803T patent/PT2547650E/pt unknown
- 2011-03-17 AP AP2012006493A patent/AP3199A/xx active
- 2011-03-17 NZ NZ602451A patent/NZ602451A/en not_active IP Right Cessation
- 2011-03-17 EA EA201201293A patent/EA022066B1/ru unknown
- 2011-03-17 BR BR112012023173-1A patent/BR112012023173B1/pt not_active IP Right Cessation
-
2012
- 2012-08-31 TN TNP2012000436A patent/TN2012000436A1/en unknown
- 2012-09-04 IL IL221783A patent/IL221783A/en not_active IP Right Cessation
- 2012-09-11 CR CR20120461A patent/CR20120461A/es unknown
- 2012-09-12 NI NI201200141A patent/NI201200141A/es unknown
- 2012-09-13 CL CL2012002541A patent/CL2012002541A1/es unknown
- 2012-09-14 EC ECSP12012156 patent/ECSP12012156A/es unknown
- 2012-09-14 HN HN2012001923A patent/HN2012001923A/es unknown
- 2012-09-17 CU CU2012000136A patent/CU20120136A7/es unknown
- 2012-09-17 GT GT201200260A patent/GT201200260A/es unknown
-
2016
- 2016-01-18 CY CY20161100041T patent/CY1117134T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012155A (es) | Hidrato del hidrocloruro de agomelatina y | |
| CU20120136A7 (es) | Hidrato del hidrobromuro de agomelatina y preparación de éste | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| CL2017001675A1 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| MX386981B (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). | |
| DOP2014000204A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| BR112013031493A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto. | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| NI201100163A (es) | Un complejo de haluro de hidrógeno de agomelatina y la preparación del mismo | |
| BR112016011170A8 (pt) | derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica | |
| ECSP13012438A (es) | Proceso para preparar compuestos antivirales | |
| CL2017000293A1 (es) | Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014) | |
| BR112012019866A8 (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto | |
| CL2011001405A1 (es) | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. | |
| ES2603227T3 (es) | Proceso para la preparación de compuestos cetólidos | |
| ES2571043T3 (es) | Preparación de dihidropiridinas | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| CO6511211A2 (es) | Composiciones estable de sns 595 y métodos de preparación | |
| MX358995B (es) | Forma amorfa estabilizada de agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen. | |
| CO6551663A2 (es) | Hodrato del hidrocloruro de agomelatina y preparacion de este | |
| JO3276B1 (ar) | طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا. | |
| AR095044A1 (es) | Sales clorhidrato de un compuesto antibiótico | |
| CU20220008A7 (es) | Forma polimórfica estable de 6-fluor0-9-metil-9h-b-carbolina | |
| PY1407085A (es) | Formas cristalinas de un inhibidor de la propil hidroxilasa | |
| UY35347A (es) | Formas cristalinas de un inhibidor de la prolil hidroxilasa |